|
|
|
Volumn 16, Issue 91, 2007, Pages 179-182
|
|
Omalizumab (asthma): Too many unknowns for an anti-lgE
[No Author Info available]
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
BETA 2 ADRENERGIC RECEPTOR BLOCKING AGENT;
BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT;
CROMOGLYCATE DISODIUM;
CYTOCHROME P450;
DRUG METABOLIZING ENZYME;
IMMUNOGLOBULIN E;
LEUKOTRIENE;
LONG ACTING DRUG;
OMALIZUMAB;
PLACEBO;
STEROID;
THEOPHYLLINE;
ANTIASTHMATIC AGENT;
ANTIIDIOTYPIC ANTIBODY;
IMMUNOSUPPRESSIVE AGENT;
MONOCLONAL ANTIBODY;
ADD ON THERAPY;
ADJUVANT THERAPY;
ANAPHYLAXIS;
ANGIONEUROTIC EDEMA;
ARTICLE;
ASTHMA;
CLINICAL TRIAL;
DISEASE EXACERBATION;
DISEASE SEVERITY;
DRUG CONTRAINDICATION;
DRUG EFFICACY;
DRUG ELIMINATION;
DRUG HYPERSENSITIVITY;
DRUG INDICATION;
DRUG MEGADOSE;
EMERGENCY CARE;
HEALTH CARE COST;
HUMAN;
HYPOTENSION;
INJECTION SITE REACTION;
LARYNX EDEMA;
LONG TERM CARE;
PARASITOSIS;
PHARMACODYNAMICS;
POSTMARKETING SURVEILLANCE;
RESPIRATORY TRACT DISEASE;
RISK BENEFIT ANALYSIS;
SKIN MANIFESTATION;
SYNCOPE;
URTICARIA;
ADOLESCENT;
ADULT;
COMPARATIVE STUDY;
COST BENEFIT ANALYSIS;
DRUG EFFECT;
EUROPE;
IMMUNOLOGY;
RANDOMIZED CONTROLLED TRIAL;
ADOLESCENT;
ADULT;
ANTI-ASTHMATIC AGENTS;
ANTIBODIES, ANTI-IDIOTYPIC;
ANTIBODIES, MONOCLONAL;
ASTHMA;
COST-BENEFIT ANALYSIS;
EUROPE;
HUMANS;
IMMUNOGLOBULIN E;
IMMUNOSUPPRESSIVE AGENTS;
RANDOMIZED CONTROLLED TRIALS;
|
|
EID: 34948882385
PISSN: 11677422
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
|
Times cited : (6)
|
|
References (7)
|
